Abstract
The well-designed, model-based cost-utility analysis by Ginsberg and colleagues provides useful information on the value for money of universal GBS screening in Israel. An extended application of the model-based approach used in the study could provide policymakers additional practical information on the budget impact of a potential universal GBS screening program. Such an approach could also be used to guide future research priorities in the prevention of GBS in Israel, by measuring the value of seeking further information to reduce the uncertainty in the cost-effectiveness of universal GBS screening.This is a commentary on http://www.ijhpr.org/content/2/1/6.
Highlights
The well-designed, model-based cost-utility analysis by Ginsberg and colleagues provides useful information on the value for money of universal group B streptococcal (GBS) screening in Israel
Ginsberg and colleagues attempt to address the question of whether Israel should expand its coverage of preventive screening against group B streptococcal (GBS) infection to all pregnant women [1]
More and more recent economic evaluation studies or health technology assessments take a model-based approach, supplementing the results obtained from empirical studies
Summary
The well-designed, model-based cost-utility analysis by Ginsberg and colleagues provides useful information on the value for money of universal GBS screening in Israel. The well-designed, model-based cost-utility analysis conducted by Ginsberg and his colleagues [1] provides an example of studies that can answer such a question.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
